Amantadine and levodopa in the treatment of Parkinson's disease

Walker, Jonathan E.; Potvin, Alfred R.; Tourtellotte, Wallace W.; Albers, James W.; Repa, Brian S.; Henderson, William G.; Snyder, Dorothy

doi:10.1002/cpt197213128

Cited by 29 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most tests were chosen from a large-scale battery of tests in use for more than a decade to measure small changes in the neurological function of normal subjects and patients in the evalua tion of neuropharmacological trials. The test battery, called the Quantitative Exami nation of Neurological Function, has been rigorously evaluated [1,10,12,13], and used in several drug studies [7,18,21,22]. A review of the development, evalua tions, and uses of the test battery is found elsewhere [11,14].…”

Section: Test Instrument and Measuresmentioning

confidence: 99%

Effects of Secobarbital on Performance upon Arousal from Stage 4 Sleep

Potvin¹,

Salamy²,

Crosier³

et al. 1975

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

Secobarbital or placebo was administered to six subjects in a random double-blind crossover design. The subjects were interrupted from stage 4 sleep and required to perform a battery of tests. Compared to control scores the results indicate that secobarbital had (1) a negligible effect (less than 5%) on hand tapping coordination and dynamic steadiness; (2) a slight (5–10%) performance decrement on hand tapping speed, critical tracking ability, step reaction time, step movement time, and mental arithmetic; (3) a moderate decrement (20–40%) on visual plus auditory tracking ability, and auditory tracking ability, and (4) a 12% improvement on static steadiness. Few changes were statistically significant. Performance was near normal upon morning awakening. Secobarbital appeared to adversely affect performance primarily on those tasks requiring fast reactions and skilled hand-eye coordination ability in response to unpredictable events.

show abstract

Section: Test Instrument and Measuresmentioning

confidence: 99%

Effects of Secobarbital on Performance upon Arousal from Stage 4 Sleep

Potvin¹,

Salamy²,

Crosier³

et al. 1975

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

show abstract

“…Crosby and colleagues identified six adequately designed RCTs (62)(63)(64)(65)(66)(67). All six trials were conducted at single centres with a total of 215 patients receiving amantadine or placebo.…”

Section: Amantadinementioning

confidence: 99%

NMDA receptors in clinical neurology: excitatory times ahead

Kalia

Salter

2008

The Lancet Neurology

378

280

View full text Add to dashboard Cite

Since the N-methyl-D-aspartate receptor (NMDAR) subunits were first cloned less than two decades ago, a substantial amount of research has been invested into understanding the physiological function of NMDARs in the healthy CNS and their pathological roles in a variety of neurological diseases. These include conditions resulting from acute excitotoxic insults (e.g. ischemic stroke, traumatic brain injury), diseases due to chronic neurodegeneration (e.g. Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis), disorders arising from sensitization of neurons (e.g. epilepsy, neuropathic pain), as well as neurodevelopmental disorders associated with NMDAR hypofunction (e.g. schizophrenia). There has been much focus on selective NMDAR antagonists which have not produced positive results in clinical trials. However, there are other NMDAR-targeted therapies used in current practice which are effective for treating certain neurological disorders. In this review, we describe the evidence for the use of these therapies and provide an overview of drugs being investigated in clinical trials. We also discuss novel NMDAR-based strategies which are emerging in clinical neurology.

show abstract

“…:': 6,16 In recent years, laboratory tests have been evaluated l -3 , 5, 7, 11, 14 and used to determine the efficacy of drugs in clinical trials.! ": 18 A method for transforming data has been described by Potvin? wherein scores can be expressed as a percentage of age-and sex-rnatched normal function and averaged into groups of composite neurological functions.…”

Section: Clinical Quantitative Neurological Examination the Clinicalmentioning

confidence: 99%

Methodology tor analyzing clinical neurological data: ACTH in multiple sclerosis

Henderson

Tourtellotte

Potvin

et al. 1978

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

From 1965 to 1968 a multicenter (USA) clinical trial was conducted to compare ACTH with placebo for the treatment of multiple sclerosis patients in a stage of acute exacerbation. Of seven evaluation systems which were used, one was a quantitative neurological examination. In this report, the quantitative neurological data have been re-evaluated using a transformation of the data which express patient scores in terms of a percentage of age- and sex-matched normal function followed by a reduction of the data into composite neurological functions vs time. The results support the positive findings of previous reports. In addition, the methodology helps to simplify the therapists' task of interpreting results by enabling him to determine how near normal function the patient came following the treatment trial.

show abstract

Amantadine and levodopa in the treatment of Parkinson's disease

Cited by 29 publications

References 5 publications

Effects of Secobarbital on Performance upon Arousal from Stage 4 Sleep

Effects of Secobarbital on Performance upon Arousal from Stage 4 Sleep

NMDA receptors in clinical neurology: excitatory times ahead

Methodology tor analyzing clinical neurological data: ACTH in multiple sclerosis

Contact Info

Product

Resources

About